Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

ClinicalTrials.gov ID: NCT07216482

Public ClinicalTrials.gov record NCT07216482. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.

Study identification

NCT ID
NCT07216482
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
996 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 10, 2025
Primary completion
Aug 2, 2026
Completion
Nov 4, 2026
Last update posted
Aug 31, 2026

2025 – 2026

United States locations

U.S. sites
35
U.S. states
17
U.S. cities
33
Facility City State ZIP Site status
Central Research Associates ( Site 0009) Birmingham Alabama 35205
G&L Research ( Site 0024) Foley Alabama 36535
Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) Phoenix Arizona 85020
Alliance for Multispecialty Research LLC ( Site 0049) Tempe Arizona 85281
Chemidox Clinical Trials ( Site 0008) Lancaster California 93534
Clinical Trials Research ( Site 0036) Sacramento California 95821
Legacy Clinical Trials ( Site 0044) Colorado Springs Colorado 80909
Alliance for Multispecialty Research, LLC ( Site 0040) Fort Myers Florida 33912
Soffer Health Institute ( Site 0046) Hollywood Florida 33020
East Coast Institute for Research ( Site 0041) Lake City Florida 32055
Inpatient Research Clinic ( Site 0017) Miami Lakes Florida 33014
Clinical Research Trials of Florida ( Site 0001) Tampa Florida 33607
Clinical Site Partners LLC, dba CSP Orlando ( Site 0014) Winter Park Florida 32789
Trialmed ( Site 0026) Chicago Illinois 60602
Great Lakes Clinical Trials - Ravenswood ( Site 0018) Chicago Illinois 60640
Midwest Institute For Clinical Research ( Site 0033) Indianapolis Indiana 46260-5310
Alliance for Multispecialty Research, LLC ( Site 0048) Newton Kansas 67114
Cotton O'Neil Clinical Research Center ( Site 0006) Topeka Kansas 66606
L-MARC Research Center ( Site 0004) Louisville Kentucky 40213
Jubilee Clinical Research ( Site 0031) Las Vegas Nevada 89106
Cardiovascular Associates of the Delaware Valley ( Site 0035) Elmer New Jersey 08318
New Mexico Clinical Research & Osteoporosis Center, Inc. ( Site 0027) Albuquerque New Mexico 87106-4725
Alliance for Multispecialty Research, LLC - Norman ( Site 0043) Norman Oklahoma 73069
Cardiology Consultants of Philadelphia Yardley ( Site 0016) Yardley Pennsylvania 19067
Provecta Research Network LLC ( Site 0022) Houston Texas 77027
Permian Research Foundation ( Site 0005) Odessa Texas 79761
LinQ Research ( Site 0025) Pearland Texas 77584
Clinical Trials of Texas, Inc. ( Site 0010) San Antonio Texas 78229
Stone Oak, LLC dba Discovery Clinical Trials (DCT) ( Site 0021) San Antonio Texas 78258
LinQ Research - Tomball ( Site 0047) Tomball Texas 77375
Conquest Research ( Site 0045) Arlington Virginia 22205
Manassas Clinical Research Center ( Site 0002) Manassas Virginia 20110
Health Research of Hampton Roads, Inc. ( Site 0013) Newport News Virginia 23606
National Clinical Research, Inc ( Site 0028) Richmond Virginia 23294
Rainier Clinical Research ( Site 0023) Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07216482, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07216482 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →